Joep H.M. van Esch

2.3k total citations · 1 hit paper
26 papers, 1.8k citations indexed

About

Joep H.M. van Esch is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Joep H.M. van Esch has authored 26 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 16 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Molecular Biology. Recurrent topics in Joep H.M. van Esch's work include Renin-Angiotensin System Studies (19 papers), Hormonal Regulation and Hypertension (16 papers) and Receptor Mechanisms and Signaling (8 papers). Joep H.M. van Esch is often cited by papers focused on Renin-Angiotensin System Studies (19 papers), Hormonal Regulation and Hypertension (16 papers) and Receptor Mechanisms and Signaling (8 papers). Joep H.M. van Esch collaborates with scholars based in Netherlands, Germany and United Kingdom. Joep H.M. van Esch's co-authors include A.H. Jan Danser, Anton H. van den Meiracker, Anton J.M. Roks, Luuk te Riet, Mariëtte H.W. Kappers, Stefan Sleijfer, Richard van Veghel, Wendy W. Batenburg, Wim J. Sluiter and Stephanie Lankhorst and has published in prestigious journals such as PLoS ONE, Circulation Research and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Joep H.M. van Esch

26 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypertension

2015 529 citations Luuk te Riet, Joep H.M. van Esch et al. Circulation Research profile →

Peers

Countries citing papers authored by Joep H.M. van Esch

Since Specialization

Citations

This map shows the geographic impact of Joep H.M. van Esch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joep H.M. van Esch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joep H.M. van Esch more than expected).

Fields of papers citing papers by Joep H.M. van Esch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joep H.M. van Esch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joep H.M. van Esch. The network helps show where Joep H.M. van Esch may publish in the future.

Co-authorship network of co-authors of Joep H.M. van Esch

This figure shows the co-authorship network connecting the top 25 collaborators of Joep H.M. van Esch. A scholar is included among the top collaborators of Joep H.M. van Esch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joep H.M. van Esch. Joep H.M. van Esch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hypertension breakdown → 2015 ·Circulation Research ·Luuk te Riet, Joep H.M. van Esch, Anton J.M. Roks, Anton H. van den Meiracker, A.H. Jan Danser	529
2	Angiotensin II Type 2 Receptor– and Acetylcholine-Mediated Relaxation 2015 ·Hypertension ·Bruno Sevá Pessôa, Denise E. Slump, (unknown), Aldo Grefhorst, Richard van Veghel, Ingrid M. Garrelds, Anton J.M. Roks, Steven A. Kushner, A.H. Jan Danser, Joep H.M. van Esch	36
3	Deterioration of kidney function by the (pro)renin receptor blocker handle region peptide in aliskiren-treated diabetic transgenic (mRen2)27 rats 2014 ·American Journal of Physiology-Renal Physiology ·Luuk te Riet, Mieke van den Heuvel, Carine J. Peutz‐Kootstra, Joep H.M. van Esch, Richard van Veghel, Ingrid M. Garrelds, (unknown), (unknown), Frank Leijten, A.H. Jan Danser, Wendy W. Batenburg	23
4	The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors in aliskiren-treated diabetic transgenic (mREN2)27 rats 2013 ·Journal of Hypertension ·Wendy W. Batenburg, Mieke van den Heuvel, Joep H.M. van Esch, Richard van Veghel, Ingrid M. Garrelds, Frank Leijten, A.H. Jan Danser	26
5	Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy 2013 ·European Journal of Endocrinology ·Rob van der Pas, Joep H.M. van Esch, Christiaan de Bruin, A.H. Jan Danser, Alberto M. Pereira, Pierre Zelissen, Romana T. Netea‐Maier, (unknown), Ingrid M. Garrelds, (unknown), Steven W. J. Lamberts, Anton H. van den Meiracker, Leo J. Hofland, Richard A. Feelders	14
6	Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress 2013 ·Antioxidants and Redox Signaling ·Stephanie Lankhorst, Mariëtte H.W. Kappers, Joep H.M. van Esch, A.H. Jan Danser, Anton H. van den Meiracker	70
7	Mechanism of hypertension and proteinuria during angiogenesis inhibition 2012 ·Journal of Hypertension ·Stephanie Lankhorst, Mariëtte H.W. Kappers, Joep H.M. van Esch, A.H. Jan Danser, Anton H. van den Meiracker	50
8	Angiotensin II type 2 receptor agonists: where should they be applied? 2012 ·Expert Opinion on Investigational Drugs ·Koen Verdonk, A.H. Jan Danser, Joep H.M. van Esch	39
9	Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression 2011 ·The Journal of Clinical Endocrinology & Metabolism ·Mariëtte H.W. Kappers, Joep H.M. van Esch, Frank Smedts, Ronald R. de Krijger, Karel Eechoute, Ron H.J. Mathijssen, Stefan Sleijfer, Frank Leijten, A.H. Jan Danser, Anton H. van den Meiracker, Theo J. Visser	79
10	Impaired Vascular Contractility and Aortic Wall Degeneration in Fibulin-4 Deficient Mice: Effect of Angiotensin II Type 1 (AT1) Receptor Blockade 2011 ·PLoS ONE ·Els Moltzer, Luuk te Riet, Sigrid M. A. Swagemakers, (unknown), Marcel Vermeij, Richard van Veghel, (unknown), Joep H.M. van Esch, Stephanie Lankhorst, (unknown), Monique C. de Waard, Dirk J. Duncker, Peter J. van der Spek, Ellen V. Rouwet, A.H. Jan Danser, Jeroen Essers	35
11	Handle Region Peptide Counteracts the Beneficial Effects of the Renin Inhibitor Aliskiren in Spontaneously Hypertensive Rats 2011 ·Hypertension ·Joep H.M. van Esch, Richard van Veghel, Ingrid M. Garrelds, Frank Leijten, (unknown), A.H. Jan Danser	32
12	The role of the renin–angiotensin system in thoracic aortic aneurysms: Clinical implications 2011 ·Pharmacology & Therapeutics ·Els Moltzer, Jeroen Essers, Joep H.M. van Esch, Jolien W. Roos‐Hesselink, A.H. Jan Danser	40
13	Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts 2010 ·Cardiovascular Research ·Joep H.M. van Esch, Florian Gembardt, Anja Sterner‐Kock, Silvia Heringer‐Walther, Thu H. Le, Dirk Laßner, Theo Stijnen, (unknown), H.-P. Schultheiss, A.H. Jan Danser, Thomas Walther	60
14	Effects of Angiotensin Metabolites in the Coronary Vascular Bed of the Spontaneously Hypertensive Rat 2009 ·Hypertension ·Els Moltzer, (unknown), Richard van Veghel, A.H. Jan Danser, Joep H.M. van Esch	52
15	Effects of angiotensin II and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the angiotensin AT2 receptor? 2008 ·European Journal of Pharmacology ·Joep H.M. van Esch, (unknown), Wendy W. Batenburg, Richard van Veghel, A.H. Jan Danser	40
16	Prorenin anno 2008 2008 ·Journal of Molecular Medicine ·A.H. Jan Danser, Wendy W. Batenburg, Joep H.M. van Esch, Manne Krop	15
17	Prorenin and the (pro)renin receptor--an update 2007 ·Nephrology Dialysis Transplantation ·A.H. Jan Danser, Wendy W. Batenburg, Joep H.M. van Esch	52
18	AT₂ receptor‐mediated vasodilation in the mouse heart depends on AT_1A receptor activation 2006 ·British Journal of Pharmacology ·Joep H.M. van Esch, Martin P. Schuijt, (unknown), (unknown), Thomas Walther, A.H. Jan Danser	39
19	Protection of Rats Against Perfluoroisobutene (PFIB)-Induced Pulmonary Edema by Curosurf andN-Acetylcysteine 2004 ·Inhalation Toxicology ·Herman P.M. van Helden, (unknown), (unknown), Marloes J.A. Joosen, Joep H.M. van Esch, (unknown), Robert V. Diemel	8
20	Selective Angiotensin-Converting Enzyme C-Domain Inhibition Is Sufficient to Prevent Angiotensin I–Induced Vasoconstriction 2004 ·Hypertension ·Joep H.M. van Esch, Beril Tom, Vincent Dive, Wendy W. Batenburg, Dimitris Georgiadis, Athanasios Yiotakis, Jeanette M.G. van Gool, (unknown), René de Vries, A.H. Jan Danser	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact